ArticleFrontiers in immunology2026

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system.

Keyuan Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.